In silico–assisted development of supersaturable preconcentrated isotropic mixture of atazanavir for augmenting biopharmaceutical performance in the presence of H2-receptor antagonist

Sheshank Sethi1 · Vikas Rana1

Accepted: 5 July 2022 / Published online: 3 August 2022
© Controlled Release Society 2022

Abstract
The therapeutic potential of atazanavir (BCS Class II drug), a highly selective inhibitor of human immunodeficiency virus (HIV-1), has been largely limited due to its low intrinsic solubility at elevated pH resulting in low oral bioavailability. Thus, the current work describes the systematic development, optimization, and evaluation of hydroxypropyl methylcellulose acetate succinate (HPMC-AS)-based supersaturable preconcentrate isotropic mixture (SP-IM) containing long-chain triglyceride to improve intestinal lymphatic transport and augment oral bioavailability of atazanavir (ATZ). A D-optimal mixture design was employed for optimization of plain IM containing corn oil, oleic acid, Tween 80, and propylene glycol, evaluating various critical quality attributes (CQAs) like particle size, polydispersity index, self-emulsification time, % transmittance, and drug content. In silico analysis and in vitro supersaturation test facilitated the selection of HPMC-AS as a best suited polymeric precipitation inhibitor (PPI) for formulating ATZ loaded SP-IM (ATZ-SP-IM). In vitro dissolution data indicated that ATZ-SP-IM exhibits superior performance in 0.025 N HCl and pH 6.8 over pure drug. Ex vivo permeation and in vivo pharmacokinetic study of ATZ-SP-IM corroborated enhanced permeation (2.03 fold) and improved drug absorption via lymphatic transport in Wistar rats. Further, the pharmacokinetic performance of ATZ-SP-IM was not affected in presence of H2 receptor antagonist. Therefore, the results showed that ATZ-SP-IM can significantly improve the biopharmaceutical attributes of ATZ so as to lay a foundation of further research on the new dosage form of ATZ.

Keywords Atazanavir · Polymeric precipitation inhibitor · In silico analysis · Lymphatic drug delivery · Oral bioavailability

Introduction
Acquired immunodeficiency syndrome (AIDS) constitutes one of the serious infectious diseases challenging the public health globally, as around 37.7 million people have been infected with till 2020. As per the World Health Organization (WHO) report submitted in the year 2020, around 1.5 million new cases appeared and 0.68 million people lost their lives [1]. In this disease, the entry of human immunodeficiency virus (HIV) into the human body weakens the immune system by destroying the vital cells and further resides in the body by making its reservoir in various anatomical (central nervous system, lymphatic system, spleen, liver, lungs, and genital tract) and cellular (macrophages, CD4 + lymphocytes, and dendritic cells) sites [2, 3]. Interventions such as AIDS counseling, educational tools, and antiretroviral drug therapy have contributed to transform HIV infection from a fatal to a manageable chronic infectious disease [4]. It has been reported that around 73% of the total infected people are receiving highly active antiretroviral therapy (HAART). The administration of HAART to the infected patients has significantly reduced the mortality and morbidity rate [5, 6]. However, the insufficient amount of the drug concentration at the reservoir site may enhance the chances of viral mutations and drug resistance [7]. Due to these possible reasons, the current therapy lacks in offering the complete eradication of the virus from the host body.

Atazanavir (ATZ) is an azapeptide derivative and the seventh addition to the protease inhibitors used for the treatment and management of HIV [8]. ATZ selectively inhibits the virus-specific processing of viral Gag and Gag-Pol
polyproteins in HIV-1 infected cells by binding onto the active site of HIV-1 protease, thus prevents the formation of mature virions. Atazanavir possess advantage over that of other protease inhibitors because of distinct resistance profile and 2 to 20 fold higher antiretroviral activity [9, 10]. Similar to the other drugs in this class, atazanavir (BCS Class II drug) is a weak base that exhibits pH dependent solubility over the physiologic pH range [11]. The ATZ exhibits low oral bioavailability (60%) potentially owing to its low solubility which might get decreased to less than 1 µg/mL when acid reducing agents are co-administered [12]. In a routine practice, administration of antiretroviral drugs generally cause secondary effects like heart burn and stomach pain, so to overcome this problem, acid reducing agents are co-administered [13–15]. The in vitro solubility profile of ATZ and available clinical data suggests that elevation in the gastric pH by acid reducing agents (ARAs) can alter the drug absorption resulting in lower systemic exposure [13, 16, 17]. Besides, ATZ undergoes extensive hepatic metabolism, efflux by P-gp transporter and high metabolism by cytochrome P450 (CYP) 3A. To augment the oral bioavailability, atazanavir is generally administered with low-dose ritonavir (known to be P-gp efflux inhibitor) [8]. Despite of improvement in the oral bioavailability, atazanavir possesses poor access into the lymphatics, which acts as a viral sanctuary for persistent HIV infection. To circumvent the aforementioned limitations, various formulations of atazanavir have been reported viz solid lipid nanoparticles (SLNs) [18], nanostructured lipid carriers (NLCs) [1], solid dispersion [8], mesoporous silica particles [15], SEDDS [19], SNEDDS [19], and nanoparticles [20]. All these formulations were reported to improve biopharmaceutical attributes by increasing the solubility and thereby dissolution in absence of ARAs. Thus, it can be interpreted that none of these strategies were able to overcome the issue of reduction in the biopharmaceutical performance of ATZ when co-administered with acid reducing agents and the lymphatic delivery simultaneously. Hence, a need was felt to develop a promising ATZ formulation that has capability to resolve the problem of low drug absorption due to precipitation of drug at an elevated pH and the targeted delivery of the atazanavir to the lymphatics.

To promote the intestinal lymphatic transport of atazanavir, lipid-based drug delivery could be exploited. Amongst various lipid-based delivery systems, an isotropic mixture (IM) of suitable oil containing long-chain triglycerides, surfactant, and co-surfactant in this regard have proved as promising drug delivery system for promoting the lymphatic transport of drug [21]. However, after oral administration of atazanavir loaded isotropic mixture, the drug could be precipitated when exposed to the gastrointestinal fluids [22]. To prevent the precipitation of the lyophilic drugs, polymeric precipitation inhibitors (PPIs) are incorporated into the IM, which are generally said to be supersaturable preconcentrate IM (SP-IM) [23]. The SP-IM represents to be a newer technology in which the PPIs intended to generate and maintain a meta-stable supersaturated state in vivo by preventing or minimizing the drug precipitation [24]. However, to the best of our knowledge, hydroxypropyl methylcellulose acetate succinate (HPMC-AS)-based SP-IM have not been investigated yet for the lymphatic uptake of atazanavir.

The aim of the present investigation, therefore, focused on QbD steered systematic development of the supersaturated preconcentrate IM (SP-IM) of ATZ containing long chain triglycerides that have a capability to augment intestinal permeation and oral bioavailability at an elevated pH and assist in promoting the lymphatic uptake for the eradication of virus from the viral sanctuaries. For this, we developed SP-IM of ATZ by using different types of polymeric precipitation inhibitors (PPIs) published in the literature reports. The developed supersaturable formulations were tested for its efficiency to inhibit precipitation with regard to dissolution efficiency and dissolution-retaining time. The best suited PPI based supersaturable formulation was extensively evaluated by in vitro, ex vivo, and in vivo study.

## Materials and methods

### Materials

Atazanavir sulfate was provided ex gratis by Sun Pharmaceutical Industries Ltd., Gurugram, India. The physicochemical properties and solubility of Atazanavir Sulfate in different solvents have been listed in Table S1; supplementary data. Corn oil, oleic acid, castor oil, sesame oil, soybean oil, and olive oil were received as a kind gift samples from Croda Inc, Mumbai, India. Labrafac Lipophilic WL 1349, Capryol PGMC, Labrafil M 2125CS, Labrasol, Labrasol ALF, Maisine 35–1, Lauroglycol, Labrafin PG, Plurisol Oleique CC497, Labrafil M 1944 CS, and Transcutol P were received as the gift samples from Gattefosse, Saint-Priest, France. Kolliphor EL, RH 40, HS 15, Vitamin E TPGS, PVP K17, Poloxamer 407, and Poloxamer 188 were received as the gift sample from BASF, Mumbai, India. Capmul MCM C10, Capmul PG8, Captex 355, and Captex 200p were received as the gift samples from Abitec Corp., Wisconsin, USA. PEG 4000, Tween 80, and propylene glycol were procured from Loba Chemie, Mumbai, India. Sefsol 218 was obtained as a gift sample from Nikko Chemical Co., Ltd., Tokyo, Japan. Grapeseed oil, muskmelon oil, Watermelon oil, and poppyseed oil were purchased from Satpat & Sons, Patiala, India. HPMC E15 was obtained as a gift sample from Colorcon Asia Pvt. Ltd., India. HPMC-AS was received as a gift sample from Shin-Etsu Chemical Co. Ltd., Japan. The solvents and chemicals employed for liquid
chromatographic studies were all of HPLC grade. All other materials employed during the studies were of analytical grade and were used as such as obtained.

Methods

Validation of analytical method

The analytical method of ATZ employing high-performance liquid chromatography (HPLC) system was validated according to US FDA and European Medical Agency guidelines of bioanalytical method validation [25]. The analytical method was validated using 50 mM potassium dihydrogen phosphate buffer pH 4.5: acetonitrile: methanol::40:45:15 and 0.07% TFA (trifluoroacetic acid) as mobile phase. The analytical method of ATZ employing high-performance liquid chromatography (HPLC) system was validated according to US FDA and European Medical Agency guidelines. The analytical method of ATZ employing high-performance liquid chromatography (HPLC) system was validated according to US FDA and European Medical Agency guidelines of bioanalytical method validation [25]. The analytical method was validated using 50 mM potassium dihydrogen phosphate buffer pH 4.5: acetonitrile: methanol::40:45:15 and 0.07% TFA (trifluoroacetic acid) as mobile phase.

The analytical method was validated using 50 mM potassium dihydrogen phosphate buffer pH 4.5: acetonitrile: methanol::40:45:15 and 0.07% TFA (trifluoroacetic acid) as mobile phase at 249 nm λmax, 0.7 mL/min flow rate; Xbridge 3.5 µm, 4.6×150 mm analytical column. Further, this estimation of ATZ was validated for linearity (200–100,000 ng/mL), limit of detection (13.62 ng/mL), limit of quantification (45.40 ng/mL), inter-assay and intra-assay precision and accuracy. The linearity equation (y = 72.26x + 3542; R² = 0.99, where “y” is the area under curve and “x” is the concentration in ng/mL) was then employed to obtain unknown ATZ concentration in various samples.

Equilibrium solubility study of ATZ in various oils, surfactants, and co-surfactants

The equilibrium solubility of ATZ was quantified in various natural oils, synthetic/semi synthetic oils, surfactants, and co-surfactants. For this purpose, an excess amount of ATZ was added to each capped glass vial formerly containing 1 g of surfactant and/or co-surfactant and/or oil and vortexed for 5 min after every 2 h for 24 h at a constant temperature (40 ± 0.5 °C) in shaking incubator at 50 rpm until the attainment of equilibrium phase [26]. An aliquot of 0.5 mL sample was withdrawn at 72 h and centrifuged at 2000 rpm (~180×g) for 10 min. The resultant supernatant was appropriately filtered through 0.45 µm membrane filter, diluted with methanol, and was examined by utilizing validated HPLC method.

Ternary phase diagram

In order to determine the levels of the material attributes (MA) for D-optimal mixture design, ternary phase diagram with selected surfactant and co-surfactant along with combination of oils was constructed [27]; each of them positioned at the sides of the triangle using Triplot version 4.1.2. After equilibrium, the time of self-micro emulsification efficiency, dispersibility, appearance, percentage transmittance (at 560 nm), and flowability was observed [28, 29]. The clear isotropic mixture regions in the diagrams were plotted, and the wider region indicated the better self-emulsification efficiency was determined.

Systematic optimization of ATZ loaded preconcentrated isotropic mixture as per mixture design

D-Optimal mixture design (Design-Expert® software version 11; Stat-Ease, Inc., Minneapolis, MN) was used to optimize the composition of the critical material attributes (CMAs) of the isotropic mixture. The range of corn oil: oleic acid (CO: OA) (1:1) (oil: X1), Tween 80 (T80) (surfactant: X2), and propylene glycol (PG) (co-surfactant: X3) were set to 0.1–0.2 g, 0.5–0.7 g, and 0.2–0.4 g, respectively (Table 1). For each formulation, the total of the composition of X1, X2, and X3 was summed to 100%, i.e., 1 g. Briefly, the ATZ loaded IM were prepared by simple admixture method. An amount of ATZ (50 mg) was dissolved in propylene glycol at 80 °C by stirring on a magnetic stirrer. Subsequently, the Tween 80 and corn oil: oleic acid (1:1) was further added as per the design matrix to form IM. Particle size (Y1; nm), polydispersity index (PDI) (Y2), self emulsification time (SET) (Y3; s), percent transmittance (%T) (Y4; %), and drug content (DC) (Y5; %) were evaluated as the critical response variables (CRVs) to optimize the ATZ loaded IM by utilizing the desirability function. The design consisted of 16 experimental runs to find an appropriate polynomial model and to evaluate the effects of CMAs on the CRVs.

Determination of CRVs as per D-optimal mixture design

The developed formulations were determined for various critical response variables (CRVs), namely, particle size (Y1), poly dispersity index (Y2), percent transmittance (Y3), drug content (Y4), and self emulsification time (Y5). The method for estimating Y1, Y2, Y3, and Y4 has been discussed in Supplementary data.

SET (Y3) The self-emulsification time of IM pre-concentrates was determined through aqueous dilution method using a standard US Pharmacopeia dissolution apparatus type II (Electrolab, Mumbai, India) [30]. The time required by IM pre-concentrates to completely emulsify in the dilution media was noted.

Selection of PPI

In silico analysis The 3D-structure of ligand (ATZ) and different PPIs like Poloxamer 188, Poloxamer 407, HPMC E15, HPMC-AS, and PVP K17 were downloaded from freely available chemical structure database, i.e., chempider. Further, the 3D structure of ligand and polymers were clean up in Chem Draw Ultra 12.0 software. Each polymer
containing one repeating unit was docked with ligand (ATZ) respectively by using the MGL tool (Autodock software version 1.5.6) (M/s GNU General Public Licence, CA, USA). For all docking calculations, the size of grids was set as 40 Å × 40 Å × 40 Å with grid spaces of 0.375 Å. Lamarkian genetic algorithms (LGA) was applied to probe the most favorable drug-excipient complex geometry. The other docking parameters were set to the default values [31–33].

After molecular docking study, the stability of the different ligand-PPIs complex was accessed by molecular dynamics simulations (MDS) for a period of 30 ns, using a freely available academic version of “Desmond” program. The solvent system was built around the ligand-PPIs complex using the TIP3P water model, and the shape of the box was kept as orthorhombic with dimensions 10×10×10 Å. The neutralization of physiological pH of the system was done by adding the Na+ counter ions, and the salt concentration was set as 0.15 M. After the energy minimization, the constant temperature was maintained with Nose–Hoover chain thermostat to attain NPT equilibration at 310 K, while constant pressure was acquired using the MartyTobias-Klein barostat. Thereafter, RMSD was calculated using the desmond program [34–36].

**In vitro supersaturation test**  To prevent the ATZ loaded IM from precipitation in the intestinal condition, supersaturable IM (SP-IM) were prepared by adding different types of polymeric precipitation inhibitors (PPIs) (i.e., Poloxamer 188, Poloxamer 407, HPMC E15, HPMC-AS and PVP K17) to the optimized IM. The SP-IM was prepared by adding different type of PPIs along with ATZ in propylene glycol. Subsequently, the Tween 80 and corn oil: oleic acid (1:1) was further added to form ATZ loaded SP-IM. PPIs are incorporated in an amount equivalent to 2.5% of the total weight of optimized IM (i.e., 0.025 g of PPI for 1 g of IM).

Table 1  D-optimal mixture design for the formulation and optimization of ATZ loaded preconcentrated isotropic mixture

| F. No. | (X₁) Oil (CO:OA) (1:1) (g) | (X₂) Surfactant (T80) (g) | (X₃) Co-surfactant (PG) (g) | (Y₁) PS (nm) | (Y₂) PDI (%) | (Y₃) % T (%) | (Y₄) DC (%) | (Y₅) SET (s) |
|---------|---------------------------|--------------------------|-----------------------------|--------------|--------------|--------------|-------------|-------------|
| 1.      | 0.1                       | 0.5                      | 0.4                         | 14.6±0.7     | 0.191±0.009  | 98.2±0.7     | 91.3±2.7    | 23±1        |
| 2.      | 0.1                       | 0.5                      | 0.4                         | 16.7±0.8     | 0.125±0.006  | 99.5±0.3     | 89.3±2.4    | 25±2        |
| 3.      | 0.175                     | 0.5875                   | 0.2375                      | 18.8±0.6     | 0.098±0.004  | 91.33±0.9    | 58.2±1.7    | 26±1        |
| 4.      | 0.1                       | 0.6                      | 0.3                         | 13.3±0.5     | 0.105±0.005  | 99.6±0.6     | 69.5±1.9    | 24±2        |
| 5.      | 0.15                      | 0.6125                   | 0.2375                      | 20.6±1.1     | 0.095±0.004  | 94.1±0.8     | 55.0±1.6    | 20±1        |
| 6.      | 0.1                       | 0.7                      | 0.2                         | 15.9±0.7     | 0.375±0.018  | 100±0.2      | 52.7±1.3    | 20±1        |
| 7.      | 0.1                       | 0.6                      | 0.3                         | 15.5±0.6     | 0.121±0.006  | 99.7±0.2     | 65.2±1.9    | 22±2        |
| 8.      | 0.125                     | 0.5375                   | 0.3375                      | 19.5±0.9     | 0.085±0.004  | 99.5±0.3     | 71.9±2.1    | 24±2        |
| 9.      | 0.2                       | 0.6                      | 0.2                         | 30.9±1.5     | 0.385±0.019  | 95.8±0.8     | 54.9±1.5    | 28±3        |
| 10.     | 0.2                       | 0.6                      | 0.2                         | 35.7±1.7     | 0.425±0.021  | 93.8±0.9     | 52.0±1.3    | 27±2        |
| 11.     | 0.15                      | 0.5                      | 0.35                        | 16.2±0.8     | 0.051±0.002  | 100±0.3      | 74.6±2.2    | 23±1        |
| 12.     | 0.125                     | 0.6375                   | 0.2375                      | 14.1±0.7     | 0.101±0.005  | 100±0.2      | 53.8±1.6    | 26±3        |
| 13.     | 0.2                       | 0.5                      | 0.3                         | 17.2±0.8     | 0.099±0.004  | 96.8±0.9     | 63.8±1.9    | 21±1        |
| 14.     | 0.15                      | 0.65                     | 0.2                         | 17.5±0.7     | 0.132±0.006  | 100±0.2      | 51.1±1.2    | 28±2        |
| 15.     | 0.2                       | 0.5                      | 0.3                         | 18.8±0.9     | 0.136±0.005  | 97.8±0.8     | 61.2±1.8    | 22±1        |
| 16.     | 0.1                       | 0.7                      | 0.2                         | 17.5±0.6     | 0.302±0.015  | 100±0.3      | 50.2±1.3    | 21±2        |

Model fitting and statistical analysis

| Responses | Model     | C.V. (%) | p-value | PRESS | R-squared | Adj R-squared | Pred R-squared | Adeq precision |
|-----------|-----------|----------|---------|-------|-----------|---------------|----------------|----------------|
| PS        | Quadratic | 17.44    | 0.0035  | 265.22| 0.7911    | 0.6866        | 0.5101         | 8.4877         |
| PDI       | Quadratic | 30.76    | 0.0004  | 0.0783| 0.8680    | 0.8021        | 0.6498         | 11.3143        |
| %T        | Special Cubic | 1.38 | 0.0025 | 43.85 | 0.8523    | 0.7538        | 0.6076         | 9.6573         |
| DC        | Quadratic | 2.96     | <0.0001 | 93.13 | 0.9860    | 0.9789        | 0.9630         | 34.0784        |
| SET       | Special Cubic | 4.03 | 0.0003 | 28.28 | 0.9130    | 0.8550        | 0.7107         | 10.8259        |

CO corn oil, OA oleic acid, T80 Tween 80, PG propylene glycol, PS particle size, PDI polydispersity index, % T percent transmittance, DC drug content, SET self-emulsification time
Additionally through this, the drug to polymer ratio was also kept in the ratio of 1:0.5. Further, the prepared formulations were subjected to in vitro supersaturation test in simulated intestinal fluid (pH 6.8) under non-sink conditions [37, 38]. A 500 mL of dissolution media was added to a 1000-mL dissolution basket equipped with a rotating paddle maintained at 37 ± 0.5 °C and 50 rpm (Electrolab, Mumbai, India). The developed formulations were firstly dissolved in 2 mL of phosphate buffer pH 6.8, and the diluted formulations were then poured into the respective basket containing dissolution media. An aliquot of 3 mL was withdrawn from different formulations at specific time intervals without volume replacement and the amount of drug at each time interval was estimated by utilizing the validated in house HPLC method. The apparent drug concentration–time profile and the duration of the supersaturated state were subsequently determined [23, 24, 39, 40]. Further, the PPI with a higher degree of supersaturation was selected for further studies.

Evaluation of optimized ATZ-SP-IM

Solubility of ATZ loaded ATZ-SP-IM formulation in different pH condition An excess amount of ATZ-SP-IM formulation was added into 10 mL of the different media (0.025 M HCl and phosphate buffer pH 6.8) in a capped conical flask (100 mL). These conical flasks were sealed and placed into an orbital shaking incubator (Remi, India), and the temperature and rpm were maintained at 37 ± 0.5 °C and 100 rpm, respectively. An aliquot of 1 mL was taken at different time intervals (4 h and 24 h), centrifuged at 6000 rpm for 10 min, filtered using a 0.45 μ membrane filter, and were examined by utilizing validated HPLC method.

Determination of PS, PDI, and zeta potential The particle size, PDI, and zeta potential of the ATZ-SP-IM were determined by dynamic light scattering technique using particle size analyzer (Nano ZS 90, M/s Malvern, Worcestershire, UK).

Transmission electron microscopy The morphological and structural behavior of the microemulsion droplet of the ATZ-SP-IM was examined by using high-resolution transmission electron microscopy (JEM 2100 Plus, Jeol, Tokyo, Japan) [28].

Stability testing of ATZ-SP-IM The storage stability of ATZ-SP-IM was assessed as per ICH Q1A (R2) guidelines under accelerated study conditions (40 ± 2 °C/75 ± 5%). The 10 g of ATZ-SP-IM sample was packed in an air tight culture tube and maintained in a stability chamber (Remi, SC-10 Plus, India). At specific time points, particle size, PDI, drug content, cloud point, signs of drug precipitation, self-emulsification time, and % transmittance were estimated to confer stability [36]. In addition, the thermodynamic stability testing of ATZ-SP-IM was also assured by freeze thaw cycle and centrifugation test as per method reported by Kamboj et al. [41].

In vitro drug release study

Dissolution studies of ATZ-SP-IM and ATZ powder were conducted using USP apparatus II (Electrolab, Mumbai, India) employing 900 ml of office of generics media (OGD media) 0.025 N HCl and phosphate buffer (pH 6.8) as the dissolution medium maintained at 37 ± 0.5 °C and 50 rpm [15, 38]. ATZ-SP-IM containing ATZ equivalent to 50 mg or ATZ powder (50 mg) loaded into hard gelatin capsule were subjected to dissolution testing. At pre-determined time intervals, an aliquot of 3 mL sample (each) was withdrawn with subsequent replacement of equivalent volumes of the medium. The percentage ATZ released at specific time intervals were determined by in house validated HPLC method.

Drug permeation study across rat’s everted intestinal sac

An everted rat gut sac experiment was performed as described in the literature reports [28, 42]. Cognizance was taken that the research work, involving drug permeation and pharmacokinetic study adheres to the guidelines for care and use of the laboratory animals. Thus, all the animal investigations were performed as per the requisite protocol approved by the Institutional Animal Ethics Committee (IAEC), Punjabi University, Patiala, India (107/99/CPCSEA/2018–05).

Male Wistar rats weighing 200–250 g were used for this study. Prior to surgical procedure, the rats were fasted overnight with free access to water. Overnight-fasted rats were sacrificed by cervical dislocation. The excised jejunal segment (length ~ 6 cm; internal diameter ~ 0.3 cm; area ~ 5.8 cm²) was immediately flushed with ice cold Kreb’s Ringer phosphate buffer (KRPB). After washing, one end of the tissue segment was then ligated with thread to one end of the thin glass rod and carefully everted on a glass rod. The prepared formulations equivalent to 50 mg of ATZ was transferred to donor compartment. The everted gut sac filled with 2 mL of KRPB solution was submerged inside the aerated (10–15 bubbles/min) bath (50 mL; 37 ± 0.5 °C) containing ATZ-SP-IM or ATZ powder. An aliquot of drug solution was withdrawn from the serosal compartment at a predetermined time intervals up to 2 h and replaced with fresh KRPB solution. The amount of ATZ permeated was determined by analyzing samples using in-house validated HPLC method. The values of flux, apparent, and relative permeability of different formulations were calculated.
In vivo pharmacokinetic and lymphatic tissue distribution study

For the in vivo pharmacokinetic study, male Wistar rats (weighing 250–280 g) were randomly divided into five groups (four rats in each group) according to the two way cross over design (n = 3, 8 time points). For accessing the ATZ concentration into the lymph nodes, rats were randomly divided into two groups (n = 3, 3 time points). All animals were fasted overnight before dosing; water was provided ad libitum throughout the study and received the following treatment:

Group A and Group B rats received ATZ-SP-IM (equivalent to 7 mg/kg of ATZ) and ATZ suspension (7 mg/kg) [8], while the rats in Group C were pretreated with cycloheximide (3 mg/kg; i.p; 0.6 mg/mL solution in normal saline) 1 h prior to the administration of ATZ-SP-IM [43]. Further, rats in Groups D and E were pretreated with famotidine (25 mg/kg; per oral; 5 mL/kg in 100 mM phosphate buffer, pH 6.5) 1 h prior to the administration of ATZ-SP-IM and ATZ suspension [12]. For estimating the drug concentration into the lymphatic tissue, Groups F and G received ATZ-SP-IM and ATZ suspension formulation. All the animals received a dose equivalent to 7 mg/kg of atazanavir.

Aliquots of blood samples (0.5 mL) were periodically withdrawn from the retro-orbital plexus of the animals at predetermined time intervals. Plasma was then harvested by centrifugation at 6000 rpm for 20 min and stored at −20 °C till further analysis. In case of tissue distribution study, lymph nodes from rats at different time intervals were collected after cervical dislocation and lymph nodes were blotted with a tissue paper. The excised tissue was homogenized in an ice-cold phosphate buffer saline solution. The extraction of ATZ from plasma and tissue homogenate was carried out by liquid–liquid extraction method [44]. The drug content was analyzed by HPLC, and standard non-compartmental pharmacokinetic parameters were calculated using in house pharmacokinetic program.

Results and discussion

Equilibrium solubility study of ATZ

Formation of stable and robust ATZ-IM without any precipitation depends upon the equilibrium solubility of ATZ in various oils, surfactants, and co-surfactants. Solubility of ATZ in different oils, surfactants, and co-surfactants has been illustrated in Fig. 1A and B. ATZ exhibited maximum solubility in oleic acid and corn oil. Oleic acid and corn oil chosen from the list of oils will assist in the lymphatic uptake of the atazanavir [45]. In case of surfactants and co-surfactants, ATZ possesses higher solubility in Tween 80 and propylene glycol. Being a non-ionic surfactant, Tween 80 is considered to be safe, effective, and an inhibitor of the P-gp efflux of atazanavir after oral ingestion [46]. In addition, propylene glycol being a co-surfactant is non volatile and compatible with gelatin capsules compared to other alcoholic co-surfactants. Based upon the equilibrium solubility studies of atazanavir, oleic acid, corn oil, Tween 80, and propylene glycol were chosen for delineating a stable and clear IM region during the ternary phase diagram studies.

Ternary phase diagram

Based on solubility study, ternary mixtures were firstly prepared by taking individual oil i.e. oleic acid or corn oil in combination with Tween 80 and propylene glycol. It was observed that oleic acid and corn oil alone does not able to form a clear and stable ternary mixture. Further, oleic acid: corn oil was used in a ratio of 1:1, 1:2 and 1:3 along with surfactant and co-surfactant to prepare a ternary mixture. In a ratio of 1:1, ternary mixture formed was clear and stable with a transmittance of more than 97% (Table S5; supplementary data). Beyond that concentration, the ternary mixtures so prepared were turbid and undergoes phase separation after 24 h. So, the ternary phase diagram comprising of oleic acid:corn oil (1:1), Tween 80, and propylene glycol was constructed (Fig. 1C). It was observed that when oil phase was taken from 0.1 to 0.2 g, the IM formed after reconstitution was clear and stable with a particle size < 100 nm and transmittance approaches towards 100%. But, when the concentration of oil phase increased to 0.25 g, the particle size of IM was increased significantly. Beyond that, the IM was translucent having particle size more 200 nm and got turbid when left aside for some time. Hence, the ternary phase diagram showed that 0.1–0.2 g oleic acid:corn oil (1:1), 0.5–0.8 g Tween 80, and 0.1–0.4 g propylene glycol could be further used to optimize the ATZ-IM.

Systematic optimization of ATZ-IM as per D-optimal mixture design

On the basis of phase diagram and screening studies (supplementary data), 16 IM were developed as per D-optimal mixture design each containing 50 mg of ATZ/g of IM. The developed formulations were further evaluated for various critical response variables (CRVs) namely particle size (Y1), PDI (Y2), self emulsification time (Y3), % transmittance (Y4), and drug content (Y5). Various CMAs and CRVs of D-optimal mixture design are summarized in Table 1. The CRVs obtained were given into Design Expert® 11 software for statistical analysis that generates polynomial equation for each respective CRVs. The magnitude of each estimated regression coefficient in the
polynomial equation indicated the relative contribution of the corresponding independent variable to the response variable. Larger magnitude of the coefficient signifies that the CMAs have greater influence on the CRVs. A positive sign of the coefficient indicates a synergistic effect, while a negative sign indicates an antagonistic effect of the coefficient on the CRVs. The mathematical models used for all the CRVs were found to be appropriate and acceptable (model $p$ value > $F$ is less than 0.01). The value of $R^2$ for all mathematical models indicates the magnificent fit of the polynomials produced by statistical analysis to the response variables ($p < 0.0001$). The values of "lack of fit" were found to be insignificant in all the mathematical models, suggesting that the models are appropriate. Further, the closeness in the magnitude of predicted (Pred) and adjusted (Adj) $R^2$ to the actual model $R^2$ also affirms the magnificent fit to the data. The equation obtained after critical material attributes (CMAs) with critical response variables (CRVs) has been illustrated below:

$$P.S = + 60.23X_1 + 15.51X_2 + 17.14X_3$$
$$- 27.44X_1X_2 - 76.69X_1X_3$$
$$- 5.51X_2X_3$$

$R^2 = 0.791; \ (model = \text{Quadratic})$

Fig. 1 Solubility analysis of ATZ in various oils (A), surfactants and co-surfactants (B), and ternary phase diagram constituting corn oil, oleic acid, Tween 80, and propylene glycol (C)
PDI = + 1.52X_1 + 0.3196X_2 + 0.1824X_3 
- 2.22X_1X_2 - 2.82X_1X_3 
- 0.5241X_2X_3 \tag{2}

R^2 = 0.8680; \text{ (model = Quadratic)}

\% Transmittance = + 69.64X_1 + 100.21X_2 + 98.91X_3 
+ 38.99X_1X_2 + 51.04X_1X_3 
+ 1.82X_2X_3 - 199.14X_1X_2X_3 \tag{3}

R^2 = 0.8523; \text{ (model = Special Cubic)}

Drug content (\%) = 388.33X_1 + 32.53X_2 + 444.18X_3 
- 289.10X_1X_2 - 1310.18X_1X_3 
- 377.44X_2X_3 R^2 = 0.9860; \text{ (model = Quadratic)} \tag{4}

Self–emulsification time = + 8.61X_1 + 20.76X_2 + 23.79X_3 
+ 52.15X_1X_2 + 19.91X_1X_3 
+ 3.45X_2X_3 - 24.91X_1X_2X_3 \tag{5}

R^2 = 0.9130; \text{ (model = Special Cubic)}

The results obtained from the polynomial equations were in concordance to the 3D response surface plot (Fig. S2).

**Numerical optimization**

Numerical optimization of ATZ loaded IM utilizing desirability approach with an aid of Design Expert 11 software was carried out to determine the optimized concentration of CMAs to generate a high-quality robust product. In the formulation design space, five critical response variables namely particle size (minimum), PDI (minimum), self-emulsification time (minimum), % transmittance (maximize), and drug content (maximize) with optimum goals were selected. The outcome of numerical optimization suggested formulation composition comprised oleic acid:corn oil (0.1 g), Tween 80 (0.5 g), and propylene glycol (0.4 g) fulfilled all the requirements of an optimized formulation because of better regulation of critical response variables (Table 2). The desirability plot of the optimized ATZ loaded IM has been illustrated in Fig. S2; supplementary data. For the above optimized formulation composition, 0.763 desirability was obtained. Table 2 manifests the predicted and the observed value of CRVs after developing the optimized formulation ($F_1$). The current findings revealed that not more than 5% biasness was observed when observed response values were correlated with predicted one. The optimized formulation was then subjected to further study.

**Selection of PPI**

**In silico analysis**

ATZ being a weakly basic drug undergoes drug precipitation in the intestinal pH. To prevent drug precipitation in the intestinal media, polymeric precipitation inhibitors (PPIs) were used to maintain the drug in the supersaturated state. ATZ being a ligand was docked with different types of PPIs via molecular docking study [47]. In the present investigations, the lowest binding energy and the intermolecular H-bond formation were considered as important criteria for inhibiting the crystallization of ATZ [48]. The H-bond surfaces between PPIs and ATZ were evident in Fig. 2. The results revealed that the intermolecular H-bonds were formed between the O-atom present in the glycosidic linkage of the PPI and H-atom of the ATZ. During molecular docking, the free energy ($\Delta G$) is used to investigate the strength of interactions between ATZ and PPIs [49]. The binding energies of all the ligand-PPIs complexes have been shown in Table 3. From the above results, it was observed that ATZ-HPMC-AS complex possesses lowest binding energy (−2.98 kcal/mol) and had a strong interaction with ATZ than any other PPIs in inhibiting the crystallization of ATZ.

**Table 2** Results of numerical optimization for the preparation and evaluation of ATZ loaded preconcentrated isotropic mixture

| Material attributes/response variables | Goal       | Lower limit | Upper limit | Predicted value | Observed value | % bias |
|---------------------------------------|------------|-------------|-------------|-----------------|----------------|--------|
| Corn oil: oleic acid (X_1) (g)        | Is in range| 0.1         | 0.2         | 0.1             | 0.1            |        |
| Tween 80 (X_2) (g)                    | Is in range| 0.5         | 0.7         | 0.5             | 0.5            |        |
| Propylene glycol (X_3) (g)            | Is in range| 0.2         | 0.4         | 0.4             | 0.4            |        |
| Particle size (Y_1) (nm)              | Minimize   | 13.37       | 35.73       | 17.13           | 15.73          |        |
| PDI (Y_2)                             | Minimize   | 0.051       | 0.425       | 0.201           | 0.222          |        |
| Self-emulsification time (Y_3) (s)    | Minimize   | 20          | 28          | 23.78           | 25             |        |
| % Transmittance (Y_4) (%)             | Maximize   | 91.33       | 100         | 98.91           | 99.6           |        |
| Drug content (Y_5) (%)                | Maximize   | 50.29       | 91.3        | 90.42           | 94.7           |        |
and prolonging the stabilized supersaturation state in intestinal pH. However, the docking study was usually established for ligand-PPI interaction in the absence of H₂O molecules that would be a demerit for the theoretical verification of our results. This flaw of docking study was rectified by carrying out further dynamics simulations for the period of 30 ns in the build system.

While running the MD simulations, the root-mean-square deviation (RMSD) is usually used to study the stability of the ligand-PPIs complex [32]. From Fig. S3; supplementary data, it was concluded that all the ATZ-PPI complexes could arrive at the equilibrium state but ATZ-HPMC-AS complex was able to attain the stability at the earliest with a RMSD fluctuations less than 1.5 Å. The solvent-accessible surface

Table 3  Results of ATZ-polymer precipitation inhibitor’s surface docking

| S. no. | Drug-PPIs Complex       | Lowest binding energy (kcal/mol) |
|-------|-------------------------|----------------------------------|
| 1.    | ATZ-Poloxamer 188       | +1.51                            |
| 2.    | ATZ-Poloxamer 407       | +0.44                            |
| 3.    | ATZ-PVP K17             | −1.49                            |
| 4.    | ATZ-HPMC AS             | −2.98                            |
| 5.    | ATZ-HPMC E15            | −1.53                            |

Stability study of ATZ-SP-IM as per ICH Q1A (R2) guidelines

| Stability study                        | 0  | 1  | 2  | 3  |
|----------------------------------------|----|----|----|----|
| Time (months)                          |    |    |    |    |
| Particle Size                          | 14.42 ± 1.9 | 14.5 ± 1.4 | 15.65 ± 1.2 | 16.55 ± 1.5 |
| PDI                                    | 0.186 ± 0.02 | 0.262 ± 0.01 | 0.274 ± 0.03 | 0.302 ± 0.02 |
| Drug content (%)                       | 94.6 ± 3.2 | 94.5 ± 3.1 | 94.1 ± 2.8 | 93.8 ± 3.3 |
| Cloud point (°C)                       | 73 ± 4 | 74 ± 2 | 73 ± 3 | 72 ± 3 |
| Drug precipitation                     | X   | X   | X   | X   |
| Self-emulsification time (s)           | 28 ± 3 | 27 ± 2 | 25 ± 3 | 27 ± 2 |
| % Transmittance (%)                   | 99.7 ± 1.1 | 99.7 ± 1.2 | 99.3 ± 1.3 | 99.3 ± 1.1 |
| Thermodynamic stability                |     |     |     |     |
| Centrifugation                         | X   | X   | X   | X   |
| Phase separation                       | X   | X   | X   | X   |
| Freeze thaw cycle                      |     |     |     |     |
| 4 °C                                   | X   | X   | X   | X   |
| 40 °C                                  | X   | X   | X   | X   |
area (SASA) of solute was also calculated to compare the hydrophilic property of the ATZ-PPI complex [47]. After carrying out the MD simulation, it was observed that all polymers except HPMC-AS were able to interact with the system constituting the H2O molecules. The existence of carbonyl and the ester moiety in the HPMC-AS exhibited a large hydrophobic area than other PPIs, which could help HPMC-AS to interact greatly with the hydrophobic moiety of the ATZ molecule [48]. Thus, the above observations provide an insight into the potential of the HPMC-AS to inhibit the crystallization of ATZ in the intestinal media.

In vitro supersaturation test

To validate the results obtained from in silico analysis, in vitro supersaturation test was conducted. The in vitro supersaturation test was conducted for optimized ATZ-IM containing different polymeric precipitation inhibitors (PPIs) in 500 mL of simulated intestinal fluid (pH 6.8) under non-sink conditions. The performance of PPIs was evaluated by comparing the apparent concentration of the drug v/s time, as illustrated in Fig. 3A. The initial drug concentration of ATZ was found out to be 0.1 mg/mL (based on the dilution factor of 500, i.e., 1 g of ATZ-IM containing 50 mg of ATZ dissolved in 500 mL of simulated intestinal fluid) before the commencement of supersaturation test. After initiating the experiment, at time t = 5 min, the apparent drug concentration was found out to be 0.034 mg/mL for HPMC E15, 0.086 mg/mL for HPMC-AS, 0.024 mg/mL for PVP K17, 0.028 mg/mL for Poloxamer 188, and 0.024 mg/mL for poloxamer 407, respectively. A rapid decline in the apparent drug concentration was observed in case of HPMC E15, PVP K17, Poloxamer 188, and Poloxamer 507 (0.004 mg/mL for all the PPIs), while the HPMC-AS maintains the supersaturated state (0.041 mg/mL) to a great extent. From the outcome of in vitro supersaturation test, it was concluded that HPMC-AS was found successful in inhibiting the crystallization of ATZ in intestinal media. Hence, HPMC-AS was selected as PPIs in formulating ATZ-SP-IM for further investigation.

Fig. 3 Apparent drug concentration–time profile for various PPIs, B particle size, C zeta potential, and D TEM image of optimized ATZ-SP-IM
**Evaluation of optimized ATZ-SP-IM**

**Solubility of ATZ loaded ATZ-SP-IM formulation in different pH condition**

To investigate the effect of pH on the solubility of ATZ loaded ATZ-SP-IM, the equilibrium solubility of ATZ-SP-IM formulation was estimated in two pH conditions (0.025 M HCl and phosphate buffer pH 6.8). The results suggested $2.18 \pm 0.05 \, \text{mg/mL}$ and $1.2 \pm 0.06 \, \text{mg/mL}$ solubility of ATZ when loaded in ATZ-SP-IM after 4 h in 0.025 M HCl and pH 6.8, respectively. No significant change in the solubility of ATZ was observed in 0.025 M HCl after 24 h. However, in case of pH 6.8, the solubility was decreased to 3.87 folds after 24 h of incubation period, i.e., $0.31 \pm 0.01 \, \text{mg/mL}$.

**Determination of PS, PDI, and zeta potential**

The developed formulation was evaluated for particle size, PDI, and zeta potential. The particle size and PDI are the critical indices for assessing the self-emulsification performance of an isotropic mixture, as they determine the overall emulsification rate, extent of drug release and absorption [50]. During the particle size and PDI analysis, it was observed that ATZ-SP-IM exhibited a mean particle size of $14.42 \pm 1.9 \, \text{nm}$ and a PDI of $0.186 \pm 0.02$ (Fig. 3B). The smaller particle size could contribute to effective drug absorption and hence enhanced oral bioavailability of ATZ could be achieved [51]. No significant difference was observed in particle size and PDI when HPMC-AS was incorporated into ATZ-IM. The findings clearly vouch the presence of nanosized globules in the IM with a monodisperse nature of their distribution, thus fulfilling the requisite of SP-IM as per the published literature reports [52]. The zeta potential of the SP-IM was estimated to be $-25.7 \pm 2.4 \, \text{mV}$ (Fig. 3C). The negative zeta potential was ascribed to the presence of free fatty acids in the formulation [53]. Beside the electrostatic repulsion between droplets, Brownian motion was sufficient to overcome gravitational separation forces, thereby preventing precipitation to improve stability [54]. The above results suggested that ATZ-SP-IM generated a more stable system.

**Transmission electron microscopy**

The TEM images of reconstituted ATZ-SP-IM illustrated in Figs. 3D and S6 (low magnification image) exhibited the presence of spherically shaped oil globules. In addition, no sign of drug precipitation was observed suggesting that ATZ is present in stable and solubilized form. Although, the TEM analysis also revealed that oil droplets retain their integrity in terms of morphology, uniformity in size and shape after reconstituting ATZ-SP-IM.

**Stability testing of ATZ-SP-IM**

The ATZ-SP-IM was subjected to accelerated stability studies for a time period of 3 months. The results of particle size analysis and PDI at different time intervals shows that no significant change in the values of particle size and PDI was observed when ATZ-SP-IM was kept in a stability chamber. No significant change in the values of drug content, cloud point, self-emulsification time, and % transmittance was observed during the study (Table 3). Hence, it can be concluded that ATZ-SP-IM exhibited good shelf life. During thermodynamic stability study, no signs of phase separation or drug precipitation were observed when ATZ-SP-IM was subjected to centrifugation test (Table 3). The freeze thaw cycles did not able to change the clarity and stability of ATZ-SP-IM. The above results suggested that the developed formulation is an isotropic mixture with high stability attributes.

**In vitro drug release study**

To demonstrate the superiority of the SP-IM, dissolution profiles of ATZ from ATZ-SP-IM and ATZ powder loaded in hard gelatin capsule were determined in both 0.025 N HCl (OGD media) and intestinal pH 6.8 (Fig. 4). Being a weakly basic drug, ATZ powder exhibited higher drug release in 0.025 M HCl (Fig. 4A). It was observed that more than 90% of ATZ was release in 45 min. In contrast, ATZ-SP-IM exhibited similar behavior in 0.025 N HCl but persistently at a faster release rate. The ATZ-SP-IM releases more than 90% drug and achieved a plateau state within 10 min (Fig. 4A). This predominantly occurs due to the presence to non-ionic surfactant (Tween 80) in ATZ-SP-IM. It has been reported that surfactants with higher hydrophilic-lipophilic balance (HLB) values show higher emulsification ability and allow rapid dispersion of oil in the aqueous phase, producing nanosized oil-in-water emulsion. In case of intestinal pH, ATZ powder undergoes only 36% of drug release in 3 h of time course (Fig. 4B). The above results has been evident by the literature reports that ATZ solubility gets reduced to less than 1 µg/mL when pH goes beyond 3 [12]. On the other hand, the ATZ-SP-IM showed more than 80% of drug release in 15 min with a maximum of 93% within 90 min (Fig. 4B). The presence of HPMC-AS in the IM decelerates the crystallization of ATZ and maintaining the drug in the supersaturated state leading to the higher drug release in the intestinal pH. Overall, the above results clearly demonstrate the improved dissolution characteristics of ATZ-SP-IM.
Fig. 4 Dissolution profile of ATZ from ATZ powder and SP-IM in A 0.025 N HCl, B pH 6.8; pharmacokinetic performance of ATZ-SP-IM and ATZ suspension after 7 mg/kg single oral dose administration in C normal rat group, D famotidine rat group, E cycloheximide rat group, and F drug concentration of ATZ at different time intervals in lymph nodes (n = 3)
Table 4 Ex vivo performance of ATZ pure drug and ATZ-SP-IM across everted rat gut sac method

| Parameters                        | ATZ pure drug | ATZ-SP-IM |
|-----------------------------------|---------------|-----------|
| Flux (µg/cm²/min)                 | 0.032<sup>a</sup> | 0.065<sup>b</sup> |
| Relative permeability (µg x mL/cm²) | 3.00<sup>a</sup> | 10.92<sup>b</sup> |
| Apparent permeability (cm/min) (× 10<sup>−6</sup>) | 0.64<sup>a</sup> | 1.3<sup>b</sup> |

Pharmacokinetic parameters of ATZ suspension and ATZ-SP-IM after 7 mg/kg single dose to various wistar rats groups

| Parameters                  | Group-A ATZ Suspension | Group-B ATZ-SP-IM | Group-C ATZ + Famotidine | Group-D ATZ-SP-IM + Famotidine | Group E ATZ-SP-IM + Cycloheximide |
|-----------------------------|------------------------|------------------|--------------------------|-------------------------------|----------------------------------|
| C<sub>max</sub> (µg/mL)     | 14.46 ± 3.72<sup>a</sup> | 28.76 ± 5.43<sup>b</sup> | 7.87 ± 2.39<sup>c</sup> | 26.25 ± 4.31<sup>d</sup> | 20.39 ± 3.01<sup>e</sup> |
| T<sub>max</sub> (h)         | 0.25 ± 0.01<sup>a</sup> | 0.5 ± 0.02<sup>b</sup> | 0.25 ± 0.01<sup>c</sup> | 0.5 ± 0.02<sup>d</sup> | 0.5 ± 0.02<sup>e</sup> |
| AUC (µg x h/mL)             | 60.25 ± 4.01<sup>a</sup> | 95.47 ± 5.77<sup>b</sup> | 28.18 ± 3.40<sup>c</sup> | 96.51 ± 4.82<sup>d</sup> | 72.49 ± 3.92<sup>e</sup> |
| AUMC (µg x h²/mL)           | 374.18 ± 21.7<sup>a</sup> | 685.35 ± 34.2<sup>b</sup> | 152.82 ± 15.6<sup>c</sup> | 676.37 ± 39.6<sup>d</sup> | 474.69 ± 23.7<sup>e</sup> |
| T<sub>1/2</sub> (h)         | 4.28 ± 0.21<sup>a</sup> | 6.30 ± 0.31<sup>b</sup> | 4.14 ± 0.20<sup>c</sup> | 6.27 ± 0.29<sup>d</sup> | 6.22 ± 0.30<sup>e</sup> |
| MRT (h)                     | 6.07 ± 0.30<sup>a</sup> | 6.75 ± 0.33<sup>b</sup> | 5.28 ± 0.26<sup>c</sup> | 6.71 ± 0.27<sup>d</sup> | 6.26 ± 0.28<sup>e</sup> |
| K<sub>e</sub> (h⁻¹)         | 0.161 ± 0.008<sup>a</sup> | 0.11 ± 0.005<sup>b</sup> | 0.167 ± 0.008<sup>c</sup> | 0.110 ± 0.005<sup>d</sup> | 0.111 ± 0.004<sup>e</sup> |
| rF                           | 1                      | 1.58             | 1                        | 3.42                          | -                                |

C<sub>max</sub> peak plasma concentration, T<sub>max</sub> time to peak plasma concentration, AUC area under the concentration–time curve, AUMC Area under the moment curve, MRT mean residence time, K<sub>e</sub> elimination rate constant, T<sub>1/2</sub> half-life, rF relative oral bioavailability

<sup>a,b</sup> Means within the same row, labeled with the same letter in ATZ pure drug and ATZ-SP-IM group, do not statistically differ from each other (p > 0.05)

<sup>a,b</sup> Means within the same row, labeled with the same letter in Groups A and B, do not statistically differ from each other (p > 0.05)

<sup>c,d</sup> Means within the same row, labeled with the same letter in Groups C and D, do not statistically differ from each other (p > 0.05)

<sup>b,c</sup> Means within the same row, labeled with the same letter in Groups B and E, do not statistically differ from each other (p > 0.05)
Drug permeation study across rat’s everted intestinal sac

The ex vivo performance of ATZ-SP-IM and ATZ powder was carried out by using rat’s everted intestinal sac. To compare the results, flux (µg/cm²/min), apparent permeability (cm/min), and relative permeability were calculated (Table 4). The rate of permeation (flux) of pure ATZ across intestinal wall was calculated to be 0.032 µg/cm²/min, suggesting that ATZ belongs to BCS-Class II drug, while the ATZ release from SP-IM was found to be 0.065 µg/cm²/min, which was calculated to be 2.03 folds enhancement in flux. The results also suggested a 3.63-fold enhancement in relative permeability of ATZ in case of ATZ-SP-IM formulation. The enhanced permeability can be attributed to the larger concentration gradient created by the increased solubility of the ATZ into the SP-IM. From the above results, it can be postulated that larger surface area of nanoparticulates provided by ATZ-SP-IM increases the adherence to the intestinal membrane which in turn enhances the intestinal transport of the drug [28].

In-vivo pharmacokinetic and lymphatic tissue distribution study

The in vivo animal pharmacokinetic study employing two-way crossover design was carried out to compare the pharmacokinetic profile of ATZ-SP-IM with pure ATZ. The observed plasma concentration–time profile after oral administration of ATZ in the form of pure drug and ATZ-SP-IM is depicted in Fig. 4C, and the non-compartmental pharmacokinetic parameters have been summarized in Table 4. The peak plasma concentration (Cmax) value of atazanavir after a single dose of suspension as a reference product and SP-IM as a test formulation were found to be 14.46 ± 3.72 µg/mL and 28.76 ± 5.43 µg/mL, respectively. A significant enhancement in Cmax (1.98 fold) was evident, when ATZ-SP-IM was administered. The area under curve (AUC) was also found to be 1.8 fold enhanced for ATZ-SP-IM (95.47 ± 5.77 µg/mL) than for ATZ suspension (60.25 ± 4.01 µg/mL). The half-life (t1/2) of ATZ-SP-IM was found to be 1.47 fold increased as compared to pure ATZ. In line with the AUC values, the mean residence time (MRT) in case of ATZ-SP-IM was found to be increased when compared with pure ATZ. The improvement in the pharmacokinetic performance of ATZ could be attributed to the high solubility of ATZ into the SP-IM components and a large surface area of microemulsion formed after reconstitution with GI fluids may be responsible for promoting gastrointestinal absorption and improving the ATZ oral bioavailability.

The effect of histamine H2 receptor antagonist (famotidine) on the pharmacokinetic performance of ATZ-SP-IM and pure ATZ was also investigated. A sharp decline in the value of Cmax and AUC was observed when pure ATZ was administered to the rats pretreated with famotidine (Table 4). This sudden decrease in the pharmacokinetic parameters could be due to the steep decline in the solubility of ATZ with respect to the change in the gastric pH. At elevated pH, the solubility of ATZ decreases that may lead to insufficient dissolution in the stomach due to which the absorption of ATZ from the GIT decreased [12]. However, the absorption of ATZ does not get affected when drug was administered into SP-IM (Table 4; Fig. 4D). Such type of behavior was ascribed to the presence of HPMC-AS in the SP-IM that induced and maintained the drug in the supersaturated state over a period of time till absorption. This augmentation in the rate and extent of drug bioavailability from SP-IM would eventually results in significant escalation in the intensity of therapeutic effect of atazanavir too.

The intestinal lymphatic transport of any formulation is elucidated by comparing the pharmacokinetic profiles in animals pretreated with cycloheximide, a chylomicron flow blocker. As compared to pure ATZ, the ATZ-SP-IM exhibited significant increase in the extent of oral bioavailability in rats (i.e., nearly 1.58 fold), evident from the corresponding values of the AUC (Table 4). However, a remarkable change in the value of AUC was observed when ATZ-SP-IM formulation was administered to rats group pretreated with cycloheximide over ATZ-SP-IM control group (Fig. 4E). A considerable 1.31 fold decrease in the value of AUC could be ascribed solely to the inhibition of the lymphatic pathways caused by blockage of chylomicron flow. Hence, it can be said that absorption of ATZ was highly affected by cycloheximide and intestinal lymphatic system was involved in the absorption of ATZ-SP-IM. The intestinal lymphatic uptake of ATZ-SP-IM occurs due to the presence of high concentration of surfactant and the long chain triglycerides in the formulation. In our case, presence of corn oil and oleic acid as long chain triglycerides assists in the lymphatic transport of ATZ [45]. Besides, Tween 80 being a surfactant has been reported to inhibit P-glycoprotein (P-gp) activity which might be another benefit for enhanced permeability and intestinal lymphatic transport, resulting in enhanced oral bioavailability [55]. To validate the results of chylomicron flow blocking approach in analyzing the drug transport to the lymphatics, concentration of ATZ in the lymph nodes was also estimated. For this, rats were administered orally with ATZ-SP-IM and ATZ suspension at a dose of 7 mg/kg. The concentration of ATZ in the lymph nodes at specific time intervals was estimated by excising the lymph nodes after cervical dislocation. It was observed that the rats administered with supersaturable preconcentrated isotropic mixture (ATZ-SP-IM) exhibited higher concentration of ATZ in the lymph nodes over that of putative form. The enhanced drug concentration in the lymph nodes could be ascribed to the presence of long chain fatty acids in the
supersaturable formulation which assists in the transport of ATZ to the lymphatics. The improved distribution of ATZ to the lymphatics would potentially result in the site-specific targeted drug delivery, inhibition of the HIV and further prevents the suppression of biodistribution of the virus to the other vital organs.

Conclusion

The current investigation successfully vouch the QbD-based systematic development of optimized ATZ loaded SP-IM with enhanced biopharmaceutical attributes coupled with lymphatic targeting of BCS Class-II drug, atazanavir, exhibiting pH dependent solubility. The optimized ATZ loaded IM exhibited nanometric particle size, uniform particle distribution (0.186 ± 0.02) and faster emulsification efficiency. A combination of in silico and in vitro analysis indicated that presence of HPMC-AS in SP-IM had inhibitory effect on drug precipitation and manifested immediate drug release as compared to putative atazanavir. Further, extensive evaluation through ex vivo and in vivo studies with ATZ-SP-IM revealed remarkable augmentations in the permeability, lymphatic uptake and systemic availability. In addition, the presence or absence of ARAs did not alter the biopharmaceutical performance of ATZ when loaded into SP-IM. Overall, the present investigation suggested the overwhelming influence of HPMC-AS and IM in improving the biopharmaceutical attributes of ATZ. Further, the strategic formulation technology employed in this present investigation can be extrapolated to other similar antiretroviral drugs for enhancing upon their targeting potential to the lymphatic system for AIDS management.

Supplementary Information  The online version contains supplementary material at https://doi.org/10.1007/s13346-022-01210-w.

Acknowledgements  The authors would like to acknowledge the Council of Scientific and Industrial Research (CSIR), New Delhi, India, for providing Direct-SRF, sanction no 09/140(0176)/2019-EMR-I. The generous supply of atazanavir sulfate from Sun Pharmaceutical Industries Ltd., Gurugram, India, is also appreciated. The authors are also thankful to Gattefosse, BASF, and Croda Chemicals, India, for their kind donation of the surfactants and the oil used in this study.

Author contribution  All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by all authors. All authors read and approved the final manuscript.

Funding  This research work was supported by Council of Scientific and Industrial Research (CSIR), New Delhi, India (Grant No. 09/140(0176)/2019-EMR-I).

Availability of data and materials  The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

This article was preprinted on Research Square preprint server (https://doi.org/10.21203/rs.3.rs-1149372/v1).

Ethical approval  The research work involving ex vivo permeation and in vivo pharmacokinetics adheres to the guidelines for care and use of the laboratory animals. Thus, all the animal investigations were performed as per the requisite protocol approved by the Institutional Animal Ethics Committee (IAEC), Punjabi University, Patiala, India (Approval No. 107/99/CPCSEA/2018–05).

Consent for publication  No human volunteers or data related to human volunteers were involved in this research work, as the proposed study was performed on rodents. Therefore, no consent was taken from human volunteers to publish manuscript.

Competing interests  The authors declare no competing interests.

References

1. Khan S, Rehman S, Nabi B, Iqubal A, Nehal N, Fahmy UA, Kotta S, Baboota S, Md S, Ali J. Boosting the brain delivery of Atazanavir through nanostructured lipid carrier-based approach for mitigating neuroaids. Pharmaceuticals. 2020;12:1059.
2. Sarma A, Das MK. Formulation by Design (FbD) approach to develop Tenofovir Disoproxil Fumarate loaded nanostructured lipid carriers (NLCs) for the aptness of nose to brain delivery. J Drug Deliv Ther. 2019;9:148–59.
3. Bagasley O. A unified concept of HIV latency. Expert Opin Biol Ther. 2006;6:1135–49.
4. Ojewole E, Mackraj N, Naidoo P, Govender T. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm. 2008;70:697–710.
5. Naidoo P. Barriers to HIV care and treatment by doctors: a review of the literature. S Afr Fam Pract. 2006;48:1.
6. Lei B, Zha W, Wang Y, Wen C, Studer EJ, Wang X, Jin F, Wang G, Zhang L, Zhou H. Development of a novel self-microemulsifying drug delivery system for reducing HIV protease inhibitor-induced intestinal epithelial barrier dysfunction. Mol Pharm. 2010;7:844–53.
7. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence.Curr HIV Res. 2008;6:388–400.
8. Fukushima K, Terasaka S, Haraya K, Kodera S, Seki Y, Wada A, Ito Y, Shibata N, Sugiyoka N, Takada K. Pharmacological approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system. Biol Pharm Bull. 2007;30:733–8.
9. Colombo R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Identification of IS0L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis. 2004;189:1802–10.
10. Wood R, Phunupak P, Cahn P, Pokrovskiy V, Rozenbaum W, Pantaleo G, Senion M, Murphy R, Mancini M, Kelleher T. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. JAIDS J Acquir Immune Defic Syndr. 2004;36:684–92.
11. Singh G, Pai RS. Optimized self-nanoemulsifying drug delivery system of atazanavir with enhanced oral bioavailability: in vitro/in vivo characterization. Expert Opin Drug Deliv. 2014;11:1023–32.
12. Saxena A, Shah D, Padmanabhan S, Gautam SS, Chowan GS, Mandlekar S, Desikan S. Prediction of pH dependent absorption using in vitro, in silico, and in vivo rat models: Early liability assessment during lead optimization. Eur J Pharm Sci. 2015;76:173–80.
13. Lahner E, Annibale B, Delle Fave G. Systematic review: impaired drug absorption related to the co-administration of antiserotonergic therapy. Aliment Pharmacol Ther. 2009;29:1219–1229.

14. Tomilo DL, Smith PF, Ogundele AB, Difrancesco R, Berenson CS, Eberhardt BD, Bednarzky E, Morse GD. Inhibition of atazanavir oral absorption by lanzoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy: J Hum Pharmacol Drug Ther. 2006;26:341–346.

15. Xia X, Zhou C, Baillie L, Garcia-Bennett AE. In vivo enhancement in bioavailability of atazanavir in the presence of proton-pump inhibitors using mesoporous materials. Chem Med Chem. 2012;7:43–8.

16. DeVault KR, Talley NJ. Insights into the future of gastric acid suppression. Nat Rev Gastroenterol Hepatol. 2009;6:524–32.

17. Khoblou H, Farthing C. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers. JAIDS J Acquir Immune Defic Syndr. 2005;39:503.

18. Chattopadhyay N, Zastre J, Wong H-L, Wu XY, Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res. 2008;25:2262–71.

19. Morgen M, Saxena A, Chen X-Q, Miller W, Nkansah R, Goodwin A, Cape J, Haskell R, Su C, Gudmundsson O. Lipophilic salts of poorly soluble compounds to enable high-dose lipidic SEDDS formulations in drug discovery. Eur J Pharm Biopharm. 2017;117:212–23.

20. Singh G, Pai RS. Atazanavir-loaded Eudragit RL 100 nanoparticles to improve oral bioavailability: optimization and in vitro/in vivo appraisal. Drug Delivery. 2016;23:532–9.

21. Holm R, Porter CJ, Edwards GA, Müllertz A, Kristensen HG, Charman WN. Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. Eur J Pharm Sci. 2003;20:91–7.

22. Zhang N, Zhang W, Jin Y, Quan D-Q. Studies on preparation of carbamazepine (CBZ) supersaturatable self-microemulsifying formulation (S-SMEDDS) formulation and relative bioavailability in beagle dogs. Pharm Dev Technol. 2011;16:415–21.

23. Jain A, Kaur R, Beg S, Kushvah V, Jain S, Singh B. Novel cationic supersaturable nanomicellar systems of raloxifene hydrochloride with enhanced biopharmaceutical attributes. Drug Deliv Transl Res. 2018;8:670–92.

24. Jo K, Kim H, Khadka P, Jang T, Kim SJ, Hwang S-H, Lee J. Enhanced intestinal lymphatic absorption of saquinavir through supersaturated self-microemulsifying drug delivery systems. Asian J Pharm Sci. 2020;15:336–46.

25. Krishna KV, Saha RN, Singhvi G, Dubey SK. Pre-clinical pharmacokinetic-pharmacodynamic modelling and biodistribution studies of donepezil hydrochloride by a validated HPLC method. RSC Adv. 2018;8:24740–9.

26. Kamboj S, Sethi S, Rana V. Lipid based delivery of Efavirenz: an answer to its erratic absorption and food effect. Eur J Pharm Sci. 2018;123:199–216.

27. Gao H, Jia H, Dong J, Yang X, Li H, Ouyang D. Integrated in silico formulation design of self-emulsifying drug delivery systems. Acta Pharmaceutica Sinica B. 2021;11:3585–94.

28. Kamboj S, Rana V. Quality-by-design based development of a self-microemulsifying drug delivery system to reduce the effect of food on Nelfinavir mesylate. Int J Pharm. 2016;501:311–25.

29. Kamble RN, Mehta PP, Kumar A. Efavirenz self-nano-emulsifying drug delivery system: in vitro and in vivo evaluation. AAPS Pharm Sci Tech. 2016;17:1240–7.

30. Baheti A, Srivastava S, Sahoo D, Lowalekar R, Prasad Panda B, Kumar Padhi B, Raghuvanshi R. Development and pharmacokinetic evaluation of industrially viable self-microemulsifying drug delivery systems (SMEDDS) for terbinafine. Curr Drug Deliv. 2016;13:65–75.

31. Khurana RK, Bansal AK, Beg S, Burrow AJ, Katre O, Singh KK, Singh B. Enhancing biopharmaceutical attributes of phospholipid complex-loaded nanostructured lipidic carriers of mangiferin: systematic development, characterization and evaluation. Int J Pharm. 2017;518:289–306.

32. Li C, Wang J-X, Le Y, Chen J-F. Studies of bicalutamide–excipients interaction by combination of molecular docking and molecular dynamics simulation. Mol Pharm. 2013;10:2362–2369.

33. Geetha P, Sivaram AJ, Jayakumar R, Mohan CG. Integration of in silico modeling, prediction by binding energy and experimental approach to study the amphorous chitin nanocarriers for cancer drug delivery. Carbohyd Polym. 2016;142:240–9.

34. Patel MR, Lamprou DA, Vavia PR. Synthesis, characterization, and drug delivery application of self-assembling amphiphilic cyclodextrin. AAPS Pharm Sci Tech. 2020;21:1–16.

35. Choudhary S, Silakari O. hCSE1 and hCSE2 mediated activation of epalrestat-antioxidant mutual prodrugs: Unwinding the hydrolytic mechanism using in silico approaches. J Mol Graph Model. 2019;91:148–63.

36. Dhumal DM, Akamanchi K. Self-microemulsifying drug delivery system for campothecin using new bicephalous heterolipid with tertiary-amine as branching element. Int J Pharm. 2018;541:48–55.

37. Sun DD, Wen H, Taylor LS. Non-sink dissolution conditions for predicting product quality and in vivo performance of supersaturating drug delivery systems. J Pharm Sci. 2016;105:2477–88.

38. Hate SS, Reutzel-Edens SM, Taylor LS. Interplay of adsorption, supersaturation and the presence of an absorptive sink on drug release from mesoporous silica-based formulations. Pharm Res. 2020;37:1–18.

39. Bandypadhyay S, Katre O, Singh B. Development of optimized supersaturatable self-nanoemulsifying systems of ezetimibe: effect of polymers and efflux transporters. Expert Opin Drug Deliv. 2014;11:479–92.

40. Jaisamut P, Wiwattanawongka G, Graidist P, Sangsen Y, Wiwattanapatee R. Enhanced oral bioavailability of curcumin using a supersaturatable self-microemulsifying system incorporating a hydrophilic polymer; in vitro and in vivo investigations. AAPS Pharm Sci Tech. 2018;19:730–40.

41. Kamboj S, Sharma R, Singh K, Rana V. Aprepitant loaded solid pre-concentrated microemulsion for enhanced bioavailability: a comparison with micronized aprepitant. Eur J Pharm Sci. 2015;78:90–102.

42. Ghiati D, Sinha VR. Nanoemulsions as self-emulsified drug delivery carriers for enhanced permeability of the poorly water-soluble selective β1-adrenoceptor blocker Talinolol. Nanomed: Nanotechnol Biol Med. 2012;8:618–26.

43. Patel MH, Mundada VP, Sawant KK. Novel drug delivery approach via self-microemulsifying drug delivery system for enhancing oral bioavailability of asenapine maleate: optimization, characterization, cell uptake, and in vivo pharmacokinetic studies. AAPS Pharm Sci Tech. 2019;20:1–8.

44. Yadav M, Trivedi V, Upadhyah V, Shah G, Baxi GA, Goswami S, Shrivastav PS. Comparison of extraction procedures for assessment of matrix effect for selective and reliable determination of atazanavir in human plasma by LC–ESI-MS/MS. J Chromatogr B. 2012;885:138–49.

45. Lawless E, Griffin BT, O’Mahony A, O’Driscoll CM. Exploring the impact of drug properties on the extent of intestinal lymphatic transport-in vitro and in vivo studies. Pharm Res. 2015;32:1817–29.

46. Constantinides PP, Wasan KM. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci. 2007;96:235–48.

47. Li C-X, Wang H-B, Oppong D, Wang J-X, Chen J-F, Le Y. Excipient-assisted vinpocetine nanoparticles: experiments and molecular dynamic simulations. Mol Pharmacol. 2014;11:479–92.

48. Zhang S, Sun M, Zhao Y, Song X, He Z, Wang J, Sun J. Molecular mechanism of polymer-assisting supersaturation of poorly water-soluble loratadine based on experimental observations and molecular dynamic simulations. Drug Deliv Transl Res. 2017;7:738–49.
49. Sun M, Wu C, Fu Q, Di D, Kuang X, Wang C, He Z, Wang J, Sun J. Solvent-shift strategy to identify suitable polymers to inhibit humidity-induced solid-state crystallization of lacidipine amorphous solid dispersions. Int J Pharm. 2016;503:238–46.

50. Parmar N, Singla N, Amin S, Kohli K. Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system. Colloids Surf, B. 2011;86:327–38.

51. Kakumanu S, Tagne JB, Wilson TA, Nicolosi RJ. A nanoemulsion formulation of dacarbazine reduces tumor size in a xenograft mouse epidermoid carcinoma model compared to dacarbazine suspension. Nanomed: Nanotechnol Biol Med. 2011;7:277–83.

52. Omari-Siaw E, Zhu Y, Wang H, Peng W, Firempong CK, Wang YW, Cao X, Deng W, Yu J, Xu X. Hypolipidemic potential of perillaldehyde-loaded self-nanoemulsifying delivery system in high-fat diet induced hyperlipidemic mice: formulation, in vitro and in vivo evaluation. Eur J Pharm Sci. 2016;85:112–22.

53. Li F, Song S, Guo Y, Zhao Q, Zhang X, Pan W, Yang X. Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam. Drug Deliv. 2015;22:487–98.

54. Wooster TJ, Golding M, Sanguansri P. Impact of oil type on nanoemulsion formation and Ostwald ripening stability. Langmuir. 2008;24:12758–65.

55. Goo YT, Song SH, Yeom DW, Chae BR, Yoon HY, Kim CH, Park SY, Kang TH, Lee S, Choi YW. Enhanced oral bioavailability of valsartan in rats using a supersaturable self-microemulsifying drug delivery system with P-glycoprotein inhibitors. Pharm Dev Technol. 2020;25:178–86.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.